X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (518) 518
index medicus (316) 316
epothilones - pharmacology (286) 286
antineoplastic agents - pharmacology (257) 257
oncology (226) 226
animals (224) 224
pharmacology & pharmacy (219) 219
epothilones (216) 216
female (213) 213
paclitaxel (200) 200
microtubule-stabilizing agents (148) 148
microtubules - drug effects (146) 146
epothilones - therapeutic use (143) 143
cell line, tumor (142) 142
cancer (138) 138
epothilones - chemistry (124) 124
antineoplastic agents - therapeutic use (123) 123
chemotherapy (119) 119
paclitaxel - pharmacology (117) 117
tubulin (116) 116
tubulin modulators - pharmacology (113) 113
epothilone (110) 110
tubulin - metabolism (108) 108
antineoplastic agents - chemistry (101) 101
chemistry, medicinal (98) 98
microtubules - metabolism (96) 96
mice (93) 93
breast neoplasms - drug therapy (91) 91
ixabepilone (91) 91
neoplasms - drug therapy (89) 89
male (88) 88
drug resistance, neoplasm (87) 87
taxol (87) 87
epothilones - administration & dosage (86) 86
microtubules (83) 83
structure-activity relationship (80) 80
molecular structure (78) 78
research (74) 74
middle aged (69) 69
antineoplastic agents - chemical synthesis (65) 65
epothilones - adverse effects (65) 65
antineoplastic agents (64) 64
biochemistry & molecular biology (61) 61
breast cancer (59) 59
epothilone-b analog (59) 59
tubulin modulators - therapeutic use (59) 59
aged (56) 56
adult (55) 55
antineoplastic agents - adverse effects (54) 54
dose-response relationship, drug (54) 54
antineoplastic agents - administration & dosage (53) 53
apoptosis - drug effects (53) 53
bms-247550 (53) 53
epothilone-b (53) 53
epothilones - pharmacokinetics (53) 53
metastatic breast-cancer (53) 53
apoptosis (52) 52
article (51) 51
breast neoplasms - pathology (51) 51
epothilone b (51) 51
taxoids - pharmacology (51) 51
tumor cells, cultured (51) 51
clinical trials as topic (50) 50
antimitotic agents (49) 49
drug screening assays, antitumor (48) 48
taxanes (48) 48
agents (47) 47
cell proliferation - drug effects (47) 47
epothilones - chemical synthesis (47) 47
tubulin - chemistry (47) 47
drug design (46) 46
thiazoles - pharmacology (46) 46
cells (45) 45
phase-ii trial (45) 45
taxane (45) 45
care and treatment (44) 44
drug therapy (44) 44
resistant (44) 44
treatment outcome (44) 44
medicine & public health (43) 43
analogs (42) 42
models, molecular (42) 42
pharmacology/toxicology (42) 42
tumors (42) 42
drug resistance (41) 41
mechanism (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (40) 40
common pharmacophore (40) 40
desoxyepothilone-b (40) 40
docetaxel (40) 40
neoplasm metastasis (40) 40
cancer-cells (39) 39
chemistry, multidisciplinary (39) 39
chemistry, organic (39) 39
phase-ii (39) 39
analysis (38) 38
beta-tubulin (38) 38
binding sites (38) 38
drugs (38) 38
capecitabine (37) 37
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (710) 710
French (4) 4
German (3) 3
Chinese (1) 1
Czech (1) 1
Japanese (1) 1
Polish (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 11/2015, Volume 75, Issue 17, pp. 1993 - 2016
Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | IMMUNOTOXIN RFB4(DSFV)-PE38 BL22 | PEGYLATED LIPOSOMAL DOXORUBICIN | EPOTHILONE-B ANALOG | DRUG-RESISTANT PHENOTYPE | GEMTUZUMAB OZOGAMICIN | PHASE-I TRIAL | METASTATIC BREAST-CANCER | ERIBULIN MESYLATE E7389 | PHARMACOLOGY & PHARMACY | TOXICOLOGY | ANTI-MESOTHELIN IMMUNOTOXIN | CHRONIC MYELOID-LEUKEMIA | Dioxoles - therapeutic use | Diphtheria Toxin - pharmacology | Recombinant Fusion Proteins - pharmacology | Furans - pharmacology | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Epothilones - pharmacology | Drug Discovery - methods | Antineoplastic Agents - therapeutic use | Biological Products - pharmacology | Epothilones - therapeutic use | Harringtonines - therapeutic use | Furans - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Diphtheria Toxin - therapeutic use | Immunoconjugates - pharmacology | Cytochalasins - pharmacology | Dioxoles - pharmacology | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Ketones - therapeutic use | Cytochalasins - therapeutic use | Biological Products - therapeutic use | Ketones - pharmacology | Tetrahydroisoquinolines - pharmacology | Tetrahydroisoquinolines - therapeutic use | Withanolides - pharmacology | Harringtonines - pharmacology | Interleukin-2 - pharmacology | Withanolides - therapeutic use | Antimitotic agents | Care and treatment | Chemotherapy | Usage | Clinical trials | Dosage and administration | Diagnosis | Antineoplastic agents | Cancer | Index Medicus | Review
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 03/2013, Volume 24, Issue 3, pp. 251 - 259
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2003, Volume 2, Issue 10, pp. 971 - 984
Histone deacetylase inhibitors induce hyperacetylation of the amino-terminal lysine residues of the core nucleosomal histones, which results in chromatin... 
SIGNAL-TRANSDUCTION | ACUTE-LEUKEMIA CELLS | ONCOLOGY | ACETYLATION | RESISTANCE | RECEPTOR | RAF-1 | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | TAXOL-INDUCED APOPTOSIS | HSP90 FUNCTION | Chromatin - metabolism | Phosphorylation | Taxoids - pharmacology | Coloring Agents - pharmacology | Annexin A5 - pharmacology | Humans | Epothilones - pharmacology | Multienzyme Complexes - metabolism | Deoxycytidine - pharmacology | Proteasome Endopeptidase Complex | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Sepharose - pharmacology | Cysteine Endopeptidases - metabolism | Flow Cytometry | Cyclins - metabolism | Time Factors | Antimetabolites, Antineoplastic - pharmacology | Antineoplastic Agents - pharmacology | Hydroxamic Acids - pharmacology | Detergents - pharmacology | Receptor, ErbB-2 - biosynthesis | Cyclin-Dependent Kinase Inhibitor p21 | Antibodies, Monoclonal - pharmacology | Down-Regulation | Enzyme Inhibitors - pharmacology | Tetrazolium Salts - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Blotting, Western | Precipitin Tests | Blotting, Northern | Cell Line, Tumor | Histone Deacetylase Inhibitors | Thiazoles - pharmacology | Antineoplastic Agents, Phytogenic - pharmacology | Deoxycytidine - analogs & derivatives | Microscopy, Fluorescence | Trastuzumab | Apoptosis
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2008, Volume 35, Issue 3, pp. 255 - 261
Summary Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors... 
Hematology, Oncology and Palliative Medicine | 2-Methoxyestradiol | Discodermolide | Microtubule-targeting agent | Epothilone | Halichondrin B | Microtubule | Taxane | Colchicine | Vinca alkaloid | Taccalonolide | BETA-TUBULIN | VASCULAR DISRUPTING AGENTS | SOLID TUMORS | ANTITUMOR-ACTIVITY | EVERY 28 DAYS | COMBRETASTATIN A4 PHOSPHATE | CELL LUNG-CANCER | BREAST-CANCER | STABILIZING AGENTS | ONCOLOGY | PHASE-I | Colchicine - pharmacology | Taxoids - pharmacology | Tubulin Modulators - pharmacology | Colchicine - therapeutic use | Humans | Epothilones - pharmacology | Epothilones - therapeutic use | Lactones - pharmacology | Drug Delivery Systems | Taxoids - therapeutic use | Neoplasms - genetics | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Microtubules - drug effects | Vinca Alkaloids - pharmacology | Microtubules - ultrastructure | Macrolides - pharmacology | Steroids - pharmacology | Steroids - therapeutic use | Antineoplastic Agents, Phytogenic - therapeutic use | Microtubules - physiology | Clinical Trials as Topic | Vinca Alkaloids - therapeutic use | Cell Division - drug effects | Lactones - therapeutic use | Tubulin Modulators - therapeutic use | Neoplasms - drug therapy | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Antineoplastic Agents, Phytogenic - pharmacology | Macrolides - therapeutic use | Neoplasms - pathology | Drug Screening Assays, Antitumor | Development and progression | Care and treatment | Leukemia | Analysis | Cancer | Index Medicus | Microtubule-Targeting Agent | Vinca Alkyloid
Journal Article
Cancer Letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Abstract Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics. Multi-cytotoxic drug regimens have been highly successful,... 
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | ACTIVATION | SRC | BCR-ABL | TUMOR | MECHANISMS | SIMULATION | CHEMOTHERAPY | ONCOLOGY | RESISTANCE | SYSTEMS | KINASES | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Cell culture | Values | Cell division | Cytotoxicity | Regression analysis | Kinases | Cancer therapies | Cell growth | Cell cycle | Software | Mutation | Drug dosages | Methods | Tumors | Apoptosis | Index Medicus
Journal Article
Science, ISSN 0036-8075, 2/2013, Volume 339, Issue 6119, pp. 587 - 590
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2008, Volume 63, Issue 1, pp. 157 - 166
Journal Article
Journal Article
Journal Article